NovoNordisk's high dose Wegovy (semaglutide) has shown improved weightloss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...
Eli Lilly expects its experimental weightlosspill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and NovoNordisk, which dominate the ...